Immunomodulatory Function of Interleukin-15 and Its Role in Exercise, Immunotherapy, and Cancer Outcomes.

Farley, MJ; Bartlett, DB; Skinner, TL; Schaumberg, MA; Jenkins, DG

Immunomodulatory Function of Interleukin-15 and Its Role in Exercise, Immunotherapy, and Cancer Outcomes.

Farley, MJ Bartlett, DB Skinner, TL Schaumberg, MA Jenkins, DG

Permalink

Publisher:: LIPPINCOTT WILLIAMS & WILKINS
Publication Type:: Journal Article
Citation:: Med Sci Sports Exerc, 2023, 55, (3), pp. 558-568
Issue Date:: 2023-03-01

Closed Access

	Filename	Description	Size
	Immunomodulatory Function of Interleukin-15 and Its Role in Exercise, Immunotherapy, and Cancer Outcomes.pdf		276.62 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Farley, MJ
dc.contributor.author	Bartlett, DB
dc.contributor.author	Skinner, TL
dc.contributor.author	Schaumberg, MA
dc.contributor.author	Jenkins, DG
dc.date.accessioned	2024-01-22T03:10:33Z
dc.date.available	2024-01-22T03:10:33Z
dc.date.issued	2023-03-01
dc.identifier.citation	Med Sci Sports Exerc, 2023, 55, (3), pp. 558-568
dc.identifier.issn	0195-9131
dc.identifier.issn	1530-0315
dc.identifier.uri	http://hdl.handle.net/10453/174826
dc.description.abstract	Exercise has been shown to improve physical and psychosocial outcomes for people across the cancer care continuum. A proposed mechanism underpinning the relationship between exercise and cancer outcomes is exercise-induced immunomodulation via secretion of anti-inflammatory myokines from skeletal muscle tissue. Myokines have the potential to impair cancer growth through modulation of natural killer (NK) cells and CD8+ T cells while improving the effectiveness of cancer therapies. Interleukin-15 (IL-15), one of the most abundant myokines found in skeletal muscle, has a key immunoregulatory role in supporting the proliferation and maturation of T cells and NK cells, which have a key role in the host's immune response to cancer. Furthermore, IL-15 is being explored clinically as an immunotherapy agent with doses similar to the IL-15 concentrations released by skeletal muscle during exercise. Here we review the role of IL-15 within the immune system, examine how IL-15 is produced as a myokine during exercise, and how it may improve outcomes for people with cancer, specifically as an adjuvant or neoadjuvant to immunotherapy. We summarize the available evidence showing changes in IL-15 in response to both acute exercise and training, and the results are inconsistent; higher quality research is needed to advance the understanding of how exercise-mediated increases in IL-15 potentially benefit those who are being treated for, or who have had, cancer.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	LIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartof	Med Sci Sports Exerc
dc.relation.isbasedon	10.1249/MSS.0000000000003067
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1106 Human Movement and Sports Sciences, 1116 Medical Physiology, 1117 Public Health and Health Services
dc.subject.classification	Sport Sciences
dc.subject.classification	3202 Clinical sciences
dc.subject.classification	3208 Medical physiology
dc.subject.classification	4207 Sports science and exercise
dc.subject.mesh	Humans
dc.subject.mesh	Interleukin-15
dc.subject.mesh	Exercise
dc.subject.mesh	Muscle, Skeletal
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Immunomodulation
dc.subject.mesh	Neoplasms
dc.subject.mesh	Muscle, Skeletal
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Interleukin-15
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Exercise
dc.subject.mesh	Immunomodulation
dc.subject.mesh	Humans
dc.subject.mesh	Interleukin-15
dc.subject.mesh	Exercise
dc.subject.mesh	Muscle, Skeletal
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Immunomodulation
dc.subject.mesh	Neoplasms
dc.title	Immunomodulatory Function of Interleukin-15 and Its Role in Exercise, Immunotherapy, and Cancer Outcomes.
dc.type	Journal Article
utslib.citation.volume	55
utslib.location.activity	United States
utslib.for	1106 Human Movement and Sports Sciences
utslib.for	1116 Medical Physiology
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Strength - HPRC - Human Performance Research Centre
utslib.copyright.status	closed_access	*
dc.date.updated	2024-01-22T03:10:32Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	55
utslib.citation.issue	3

Abstract:

Exercise has been shown to improve physical and psychosocial outcomes for people across the cancer care continuum. A proposed mechanism underpinning the relationship between exercise and cancer outcomes is exercise-induced immunomodulation via secretion of anti-inflammatory myokines from skeletal muscle tissue. Myokines have the potential to impair cancer growth through modulation of natural killer (NK) cells and CD8+ T cells while improving the effectiveness of cancer therapies. Interleukin-15 (IL-15), one of the most abundant myokines found in skeletal muscle, has a key immunoregulatory role in supporting the proliferation and maturation of T cells and NK cells, which have a key role in the host's immune response to cancer. Furthermore, IL-15 is being explored clinically as an immunotherapy agent with doses similar to the IL-15 concentrations released by skeletal muscle during exercise. Here we review the role of IL-15 within the immune system, examine how IL-15 is produced as a myokine during exercise, and how it may improve outcomes for people with cancer, specifically as an adjuvant or neoadjuvant to immunotherapy. We summarize the available evidence showing changes in IL-15 in response to both acute exercise and training, and the results are inconsistent; higher quality research is needed to advance the understanding of how exercise-mediated increases in IL-15 potentially benefit those who are being treated for, or who have had, cancer.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/174826